Survivin promoter-driven adenoviral Early Region 1A (Ad-Surp-E1A)

Survivin promoter-driven adenoviral Early Region 1A (E1A) is a transcriptionally regulated oncolytic adenovirus construct designed for targeted cancer therapy. This system utilizes the promoter of the Survivin gene (BIRC5), an inhibitor of apoptosis protein that is highly overexpressed in most human cancers but virtually absent in terminally differentiated normal adult tissues (Altieri, 2003, Nature Reviews Cancer). By placing the essential adenoviral replication gene, E1A, under the control of this tumor-specific promoter, viral replication is restricted to cells where the survivin promoter is active (Ulasov et al., 2007, Molecular Therapy). Upon infection of a survivin-overexpressing tumor cell, the promoter triggers E1A expression, which initiates the viral replication cycle, leading to the production of progeny virions and the eventual destruction of the cancer cell through oncolysis (Kamizono et al., 2005, Cancer Research). This approach aims to provide a high therapeutic index by maximizing tumor cell death while sparing healthy cells that do not express survivin (Zhu et al., 2004, Cancer Gene Therapy). Preclinical and clinical studies have explored this technology in various malignancies, including glioblastoma and gastrointestinal cancers, often demonstrating enhanced efficacy when combined with conventional therapies like radiation or chemotherapy (Van Houdt et al., 2006, Journal of Gene Medicine). The primary therapeutic challenges involve the host's immune response, which can neutralize the adenovirus before it reaches the target cells, and potential hepatotoxicity if the promoter exhibits leakage in liver cells (Nettelbeck, 2008, Gene Therapy).

Other names

Ad-Survivin-E1ASurvivin-responsive oncolytic adenovirusBIRC5 promoter-driven E1AConditionally replicative adenovirus-survivinAd-Surp-E1A

The construct utilizes the tumor-specific survivin promoter to drive the expression of the adenoviral E1A gene, which is essential for viral replication. In survivin-overexpressing tumor cells, the promoter is active, leading to E1A production, viral replication, and subsequent cell lysis (oncolysis). In normal cells where survivin is not expressed, the promoter remains inactive, preventing viral replication and sparing healthy tissue.